Gilmor 2002.

Methods	Seven‐week randomised, open‐label, parallel‐group, forced‐titration multicentre study.
Participants	Outpatients fulfilling DSM‐IV criteria for major depressive disorder, with a score of at least > or = 20 on the Montgomery and Asberg Depression Rating Scale (MADRS). Age range: 18‐57 years.
Interventions	Paroxetine: 38 participants. Desipramine: 14 participants. Paroxetine dose range: 10‐60 mg/day. Desipramine dose range: 50‐300 mg/day.
Outcomes	MADRS, Clinical Global Impression (CGI). Total dropout.
Notes	Funding: paroxetine manufacturer. This study was conducted in order to evaluate inhibition of norepinephrine uptake in patient with major depression, so it is not a study of efficacy or tolerability.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned to paroxetine or desipramine in a 3‐to‐1 ratio respectively".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "open‐label". No further details.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "open‐label". No further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Dichotomous outcome not reported. Adverse events were not reported. Incomplete reporting of dropout due to side effects, dropout due to inefficacy.
Selective reporting (reporting bias)	High risk	Dichotomous outcome not reported. Adverse events were not reported. Incomplete reporting of dropout due to side effects, dropout due to inefficacy.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.